Description
Hervycta 150mg Injection is a targeted therapy used in the treatment of certain types of cancer. Its active ingredient, Trastuzumab, is a monoclonal antibody that specifically targets the HER2 (Human Epidermal growth factor Receptor 2) protein. Many cancer cells, particularly in certain breast and stomach cancers, overexpress HER2. Hervycta works by binding to these HER2 receptors on cancer cells, inhibiting their growth and proliferation. It can also flag cancer cells for destruction by the body’s immune system. Hervycta is indicated for the treatment of HER2-positive breast cancer (early-stage and metastatic) and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. The dosage and duration of treatment are determined by a qualified healthcare professional based on the specific cancer type, stage, and individual patient response. Common side effects may include infusion-related reactions (fever, chills, nausea), fatigue, shortness of breath, and heart problems. It is crucial to discuss potential side effects and contraindications with your doctor. Hervycta should be stored as per the manufacturer’s instructions, typically refrigerated.
